A Novel Role of Candesartan and Ramipril in Attenuation of Liver Fibrosis in Patients with Chronic Hepatitis C Viral Infection | Chapter 7 | New Horizons in Medicine and Medical Research Vol. 11

 This research looked at how Candesartan and Ramipril affected individuals with chronic hepatitis C's liver fibrosis.

This randomised controlled prospective study included 64 participants with chronic hepatitis C and liver fibrosis. The participants were divided into three groups according to randomization: group I (control group; n=21), which got only conventional therapy; group 2 (Ramipril group; n=21); and group 3 (Candesartan group; n=22); which received just traditional therapy plus 8 mg/day oral Candesartan.

At the beginning, the demographic and laboratory data for the three research groups were statistically identical. In comparison to baseline data, the three research groups' post-treatment liver stiffness, HA and TGF-1 blood levels, and indicators of liver fibrosis all significantly decreased (p 0.001). When compared to the control group six months after therapy, patients taking Ramipril and Candesartan showed a substantial improvement in all analysed parameters. Additionally, the Candesartan group showed a significantly lower level of liver stiffness, biomarkers, and fibrosis indices when compared to the Ramipril group.

Patients with chronic hepatitis C who had liver fibrosis responded well to be successfully treated with ramipril and candesartan. A safe and effective therapy for liver fibrosis in people with chronic liver disease may be candesartan, an AT1-R antagonist that maintained anti-fibrotic action better than Ramipril.

Author(s) Details:

Tarek M. Mostafa,
Department of Clinical Pharmacy, Faculty of Pharmacy, Tanta University, Tanta, Egypt.

Gamal A. El-azab,
Department of Clinical Pharmacy, Faculty of Pharmacy, Tanta University, Tanta, Egypt.

Gamal A. Badra,
National Liver Institute, Faculty of Medicine, Menoufia University, Shebin El-kom, Egypt.

Alyaa S. Abdelwahed,
National Liver Institute, Faculty of Medicine, Menoufia University, Shebin El-kom, Egypt.

Abeer A. Elsayed,
Department of Clinical Pharmacy, Faculty of Pharmacy, Sinai University, Al-Arish, Egypt.

Please see the link here: https://stm.bookpi.org/NHMMR-V11/article/view/7142